AIDSWEEKLY Plus; Monday, February 9, 2009
Staff Medical Writers

NewsRx -- According to recent research from the United States, "In this study, human immunodeficiency virus type 1 (HIV-1)-infected blood donors were evaluated for genetic subtype and drug resistance to determine the prevalence of divergent HIV strains in the US donor population. Subtype was determined by phylogenetic analysis of viral sequences amplified by reverse transcription-polymerase chain reaction."

"The drug resistance profile of the protease and reverse transcriptase (RT) genes was determined using an HIV-1 genotyping system (ViroSeq). From 1999 through 2005, 26 recently infected donors, defined as HIV-1 RNA-positive, antibody-negative (RNA+/Ab-), were identified (yield, 1:1.61 million). Over the same period, the frequency of anti-HIV-positive donors was 1:34,700. Twenty RNA+/Ab-specimens were evaluated; all were infected with HIV-1 subtype B. Drug resistance profiles obtained for 18 donors identified one strain with protease mutation L90M that confers resistance to nelfinavir and one with RT mutation Y188H that confers resistance to nevirapine. Genetic subtype was determined for 44 of 46 HIV antibody-reactive and confirmed-positive (Ab+) specimens. Three infections (6.8%) were due to circulating recombinant forms: 2 CRF01_AE and 1 CRF02_AG. In the Ab+ group, one strain was resistant to all nucleoside RT inhibitors and one had mutations that confer resistance to protease inhibitors. The data show that antiretroviral drug resistant HIV strains are being transmitted in the United States. Overall 6.5 percent (4 of 62) of HIV-1-infected donors harbored drug-resistant strains. HIV-1 non-B strains accounted for 4.7 percent (3 of 64) of the infections in donors," wrote C.A. Brennan and colleagues (see also HIV/AIDS).

The researchers concluded: "HIV-1 subtype B is still the predominant strain in the United States; however, non-B strains are increasing."

Brennan and colleagues published their study in Transfusion (Identification of human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug-resistant strains in United States blood donors. Transfusion. 2009 Jan;49(1):125-33.

For additional information, contact C.A. Brennan, Abbott Diagnostic, Bldg AP20-Dept. 09NG, 100 Abbott Pk Rd., Abbott Park, IL 60068, USA.

Publisher contact information for the journal Transfusion is: Blackwell Publishing, 9600 Garsington Rd., Oxford OX4 2DQ, Oxon, England.

Keywords: United States, HIV/AIDS, AIDS, Acquired Immune Deficiency Syndrome, Acquired Immunodeficiency Syndrome, Antivirals, Biotechnology, Blood Transfusion, Diagnosis, Diagnostics, Drug Development, Drug Resistance, Enzyme Research, Enzymes, Enzymology, Gene Therapy, HIV, Human Immunodeficiency Virus, Immunology, Medical Device, Nonnucleoside Reverse Transcriptase Inhibitor, Polymerase, Protease Inhibitor, Proteins, Proteomics, Sexually Transmitted Disease, Transfusion Medicine, Treatment, Viral, Virology.

This article was prepared by AIDS Weekly editors from staff and other reports.

Ref: Brennan CA, Stramer SL, Holzmayer V, et al., “Identification of human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug-resistant strains in United States blood donors”, Transfusion. 2009 Jan;49(1):125-33.

2009-02-09
AW090204

Copyright © 2009 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.